Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010512 · ClinicalTrials.gov registry record · NA
Clinical Performance of Two Commercial, Daily Disposable Contact Lenses
A NA study of Myopia and Refractive Errors, sponsored by Alcon Research.
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 8
- Study locations
NCT05010512: Completed NA study of Myopia and Refractive Errors, sponsored by Alcon Research.
NCT05010512 is a NA study of Myopia and Refractive Errors that has completed, run by Alcon Research. The registered enrollment target is 112 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (58% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05010512, a NA study of Myopia and Refractive Errors, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to compare the clinical performance of DAILIES TOTAL1 ( DT1) contact lenses with Infuse contact lenses.
Primary Outcome
Distance visual acuity (VA) was assessed with study lenses in place. VA was collected for each eye separately using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity.
Conditions Studied
Interventions
- DEVICE Delefilcon A contact lenses
- DEVICE Kalifilcon A contact lenses
Study Locations (8)
Florida
- Alcon Investigator 6355 - Orlando
- Alcon Investigator 6418 - Tallahassee
Illinois
- Alcon Investigator 3950 - Bloomington
- Alcon Investigator 6614 - Franklin Park
Tennessee
- Alcon Investigator 6353 - Memphis
- Alcon Investigator 2786 - Memphis
Minnesota
- Alcon Investigator 6583 - Eden Prairie
Pennsylvania
- Alcon Investigator 3382 - Wyomissing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-08-31 |
| Est. Completion | 2021-10-12 |
| Phase | NA |
What the finished NCT05010512 record still lists
NCT05010512 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (58% lower).
The record links to 3 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Delefilcon A contact lenses is the first listed.
NCT05010512 lists 8 locations in 5 states (Florida, Illinois, Tennessee).
Frequently Asked Questions
What is clinical trial NCT05010512 about?
NCT05010512 is a clinical study titled "Clinical Performance of Two Commercial, Daily Disposable Contact Lenses". The purpose of this study is to compare the clinical performance of DAILIES TOTAL1 ( DT1) contact lenses with Infuse contact lenses.
What is the current status of trial NCT05010512?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2021-08-31. Estimated completion is 2021-10-12.
What conditions does trial NCT05010512 study?
This clinical trial studies the following conditions: Myopia, Refractive Errors, Ametropia.
What interventions are being tested in trial NCT05010512?
The interventions under investigation include: Delefilcon A contact lenses (DEVICE), Kalifilcon A contact lenses (DEVICE).
Who is sponsoring clinical trial NCT05010512?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05010512 being conducted?
This trial has 8 study locations across Florida, Illinois, Minnesota, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05010512's enrollment target sits among peer trials
112 36th of 90 higher than 55 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI